Table 1.
Baseline Clinical Characteristics (Full Analysis Set)
| Total (n=365) | Fimasartan (n=155) | Valsartan (n=157) | Olmesartan (n=53) | p-value | |
|---|---|---|---|---|---|
| Age, years | 58.34±7.68 | 57.95±8.07 | 58.99±7.06 | 57.55±8.21 | 0.6184 |
| Male | 289 (79.18) | 120 (77.42) | 125 (79.62) | 44 (83.02) | 0.6759 |
| Smoker | 76 (20.82) | 31 (20.00) | 32 (20.38) | 13 (24.53) | 0.9441 |
| Ex-smoker | 107 (29.32) | 44 (28.39) | 48 (30.57) | 15 (28.30) | 0.9000 |
| Drinking | 250 (68.49) | 105 (67.74) | 110 (70.06) | 35 (66.04) | 0.8319 |
| DM | 54 (14.79) | 24 (15.48) | 22 (14.01) | 8 (15.09) | 0.6281 |
| Duration of HTN (months) | 96.14±91.26 | 95.14±92.07 | 93.07±89.11 | 108.13±95.91 | 0.4425 |
| BMI (kg/m2) | 25.75±2.98 | 26.13±3.22 | 25.38±2.80 | 25.74±2.69 | 0.1517 |
| Hemoglobin (g/dL) | 14.58±1.31 | 14.60±1.39 | 14.53±1.27 | 14.66±1.20 | 0.5670 |
| HbA1c | 5.78±0.60 | 5.80±0.62 | 5.76±0.60 | 5.80±0.55 | 0.9085 |
| CCr (mL/min) | 89.83±25.37 | 91.89±28.61 | 87.67±23.11 | 90.22±21.20 | 0.7117 |
| SiSBP (mmHg) | 152.96±9.15 | 152.88±9.04 | 152.92±9.32 | 153.30±9.12 | 0.1609 |
| SiDBP (mmHg) | 93.24±8.09 | 93.50±8.39 | 92.85±8.07 | 93.61±7.34 | 0.8275 |
| Prior HTN medication | 279 (76.44) | 119 (76.77) | 117 (74.52) | 43 (81.13) | 0.6132 |
| Concomitant medication | 30 (8.22) | 13 (8.39) | 14 (8.92) | 3 (5.66) | 0.7531 |
Notes: The values are indicated as mean±SD or N (%). The statistical analyses are performed by using chi-squared test for categorical variables and Kruskal–Wallis test for continuous variables.
Abbreviations: DM, diabetes mellitus; HTN, hypertension; BMI, body mass index; HbA1c, glycated hemoglobin; CCr, creatinine clearance; SiSBP, sitting office systolic blood pressure; SiDBP, sitting office diastolic blood pressure; RAS, renin-angiotensin-aldosterone system.